Reprogramming of urea cycle in cancer: Mechanism, regulation and prospective therapeutic scopes

被引:6
作者
Ghosh, Noyel [1 ]
Mahalanobish, Sushweta [1 ]
Sil, Parames C. [1 ]
机构
[1] Bose Inst, Div Mol Med, P-1-12,CIT Scheme 7M, Kolkata 700054, West Bengal, India
关键词
Urea cycle; Aspartate; Carbamoyl phosphate; Arginine depletion therapy; Cancer; PEGYLATED ARGININE DEIMINASE; HUMAN ARGINASE 1; NITRIC-OXIDE; ARGININOSUCCINATE SYNTHETASE; AMINO-ACID; HEPATOCELLULAR-CARCINOMA; PROTEIN CATABOLISM; SYNTHESIS PATHWAY; METABOLISM; ASPARTATE;
D O I
10.1016/j.bcp.2024.116326
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hepatic urea cycle, previously known as ornithine cycle, is the chief biochemical pathway that deals with the disposal of excessive nitrogen in form of urea, resulted from protein breakdown and concomitant condensation of ammonia. Enzymes involved in urea cycle are expressed differentially outside hepatic tissue and are mostly involved in production of arginine from citrulline in arginine-depleted condition. Inline, cancer cells frequently adapt metabolic rewiring to support sufficient biomass production in order to sustain tumor cell survival, multiplication and subsequent growth. For the accomplishment of this aim, metabolic reprogramming in cancer cells is set in way so that cellular nitrogen and carbon repertoire can be utilized and channelized maximally towards anabolic reactions. A strategy to meet such outcome is to cut down unnecessary catabolic reactions and nitrogen elimination. Thus, transfigured urea cycle is a hallmark of neoplasia. During oncogenesis, altered expression and regulation of enzymes involved in urea cycle is a revolutionary approach meet to maximum incorporation of nitrogen for sustaining tumor specific biogenesis. Currently, we have reviewed neoplasm-specific deregulations of urea cycle-enzymes in different types and stages of cancers suggesting its context-oriented dynamic nature. Considering such insight to be valuable in terms of prospective cancer diagnosis and therapeutics adaptive evolution of deregulated urea cycle has been enlightened.
引用
收藏
页数:12
相关论文
共 123 条
[1]   A Role for Cytosolic Fumarate Hydratase in Urea Cycle Metabolism and Renal Neoplasia [J].
Adam, Julie ;
Yang, Ming ;
Bauerschmidt, Christina ;
Kitagawa, Mitsuhiro ;
O'Flaherty, Linda ;
Maheswaran, Pratheesh ;
Oezkan, Gizem ;
Sahgal, Natasha ;
Baban, Dilair ;
Kato, Keiko ;
Saito, Kaori ;
Iino, Keiko ;
Igarashi, Kaori ;
Stratford, Michael ;
Pugh, Christopher ;
Tennant, Daniel A. ;
Ludwig, Christian ;
Davies, Benjamin ;
Ratcliffe, Peter J. ;
El-Bahrawy, Mona ;
Ashrafian, Houman ;
Soga, Tomoyoshi ;
Pollard, Patrick J. .
CELL REPORTS, 2013, 3 (05) :1440-1448
[2]   Renal Cyst Formation in Fh1-Deficient Mice Is Independent of the Hif/Phd Pathway: Roles for Fumarate in KEAP1 Succination and Nrf2 Signaling [J].
Adam, Julie ;
Hatipoglu, Emine ;
O'Flaherty, Linda ;
Ternette, Nicola ;
Sahgal, Natasha ;
Lockstone, Helen ;
Baban, Dilair ;
Nye, Emma ;
Stamp, Gordon W. ;
Wolhuter, Kathryn ;
Stevens, Marcus ;
Fischer, Roman ;
Carmeliet, Peter ;
Maxwell, Patrick H. ;
Pugh, Chris W. ;
Frizzell, Norma ;
Soga, Tomoyoshi ;
Kessler, Benedikt M. ;
El-Bahrawy, Mona ;
Ratcliffe, Peter J. ;
Pollard, Patrick J. .
CANCER CELL, 2011, 20 (04) :524-537
[3]   Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells [J].
Agrawal, Vaidehi ;
Woo, Jung Hee ;
Mauldin, Jeremy P. ;
Jo, Chanhee ;
Stone, Everett M. ;
Georgiou, George ;
Frankel, Arthur E. .
ANTI-CANCER DRUGS, 2012, 23 (01) :51-64
[4]   Prognostic and Therapeutic Impact of Argininosuccinate Synthetase 1 Control in Bladder Cancer as Monitored Longitudinally by PET Imaging [J].
Allen, Michael D. ;
Phuong Luong ;
Hudson, Chantelle ;
Leyton, Julius ;
Delage, Barbara ;
Ghazaly, Essam ;
Cutts, Rosalind ;
Yuan, Ming ;
Syed, Nelofer ;
Lo Nigro, Cristiana ;
Lattanzio, Laura ;
Chmielewska-Kassassir, Malgorzata ;
Tomlinson, Ian ;
Roylance, Rebecca ;
Whitaker, Hayley C. ;
Warren, Anne Y. ;
Neal, David ;
Frezza, Christian ;
Beltran, Luis ;
Jones, Louise J. ;
Chelala, Claude ;
Wu, Bor-Wen ;
Bomalaski, John S. ;
Jackson, Robert C. ;
Lu, Yong-Jie ;
Crook, Tim ;
Lemoine, Nicholas R. ;
Mather, Stephen ;
Foster, Julie ;
Sosabowski, Jane ;
Avril, Norbert ;
Li, Chien-Feng ;
Szlosarek, Peter W. .
CANCER RESEARCH, 2014, 74 (03) :896-907
[5]   Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma [J].
Ally, Adrian ;
Balasundaram, Miruna ;
Carlsen, Rebecca ;
Chuah, Eric ;
Clarke, Amanda ;
Dhalla, Noreen ;
Holt, Robert A. ;
Jones, Steven J. M. ;
Lee, Darlene ;
Ma, Yussanne ;
Marra, Marco A. ;
Mayo, Michael ;
Moore, Richard A. ;
Mungall, Andrew J. ;
Schein, Jacqueline E. ;
Sipahimalani, Payal ;
Tam, Angela ;
Thiessen, Nina ;
Cheung, Dorothy ;
Wong, Tina ;
Brooks, Denise ;
Robertson, A. Gordon ;
Bowlby, Reanne ;
Mungall, Karen ;
Sadeghi, Sara ;
Xi, Liu ;
Covington, Kyle ;
Shinbrot, Eve ;
Wheeler, David A. ;
Gibbs, Richard A. ;
Donehower, Lawrence A. ;
Wang, Linghua ;
Bowen, Jay ;
Gastier-Foster, Julie M. ;
Gerken, Mark ;
Helsel, Carmen ;
Leraas, Kristen M. ;
Lichtenberg, Tara M. ;
Ramirez, Nilsa C. ;
Wise, Lisa ;
Zmuda, Erik ;
Gabriel, Stacey B. ;
Meyerson, Matthew ;
Cibulskis, Carrie ;
Murray, Bradley A. ;
Shih, Juliann ;
Beroukhim, Rameen ;
Cherniack, Andrew D. ;
Schumacher, Steven E. ;
Saksena, Gordon .
CELL, 2017, 169 (07) :1327-+
[6]   AGC1/2, the mitochondrial aspartate-glutamate carriers [J].
Amoedo, N. D. ;
Punzi, G. ;
Obre, E. ;
Lacombe, D. ;
De Grassi, A. ;
Pierri, C. L. ;
Rossignol, R. .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2016, 1863 (10) :2394-2412
[7]   Pegylated arginine deiminase treatment of patients with metastatic melanoma: Results from phase I and II studies [J].
Ascierto, PA ;
Scala, S ;
Castello, G ;
Daponte, A ;
Simeone, E ;
Ottaiano, A ;
Beneduce, G ;
De Rosa, V ;
Izzo, F ;
Melucci, MT ;
Ensor, CM ;
Prestayko, AW ;
Holtsberg, FW ;
Bomalaski, JS ;
Clark, MA ;
Savaraj, N ;
Fenn, LG ;
Logan, TF .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7660-7668
[8]   Argininosuccinate Synthase 1 is a Metabolic Regulator of Colorectal Cancer Pathogenicity [J].
Bateman, Leslie A. ;
Ku, Wan-Min ;
Heslin, Martin J. ;
Contreras, Carlo M. ;
Skibola, Christine F. ;
Nomura, Daniel K. .
ACS CHEMICAL BIOLOGY, 2017, 12 (04) :905-911
[9]   A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas [J].
Bean, Gregory R. ;
Kremer, Jeff C. ;
Prudner, Bethany C. ;
Schenone, Aaron D. ;
Yao, Juo-Chin ;
Schultze, Matthew B. ;
Chen, David Y. ;
Tanas, Munir R. ;
Adkins, Douglas R. ;
Bomalaski, John ;
Rubin, Brian P. ;
Michel, Loren S. ;
Van Tine, Brian A. .
CELL DEATH & DISEASE, 2016, 7 :e2406-e2406
[10]   Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers [J].
Beddowes, Emma ;
Spicer, James ;
Chan, Pui Ying ;
Khadeir, Ramsay ;
Corbacho, Javier Garcia ;
Repana, Dimitra ;
Steele, Jeremy P. ;
Schmid, Peter ;
Szyszko, Teresa ;
Cook, Gary ;
Diaz, Monica ;
Feng, Xiaoxing ;
Johnston, Amanda ;
Thomson, Jim ;
Sheaff, Michael ;
Wu, Bor-Wen ;
Bomalaski, John ;
Pacey, Simon ;
Szlosarek, Peter W. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (16) :1778-+